The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis
Open accessAbstract
Background & aims Norfloxacin is highly effective in preventing spontaneous bacterial peritonitis recurrence in cirrhosis, but its role in the primary prevention of this complication is uncertain.Methods Patients with cirrhosis and low protein ascitic levels (<15 g/L) with advanced liver failure (Child-Pugh score > or = 9 points with serum bilirubin level > or = 3 mg/dL) or impaired renal function (serum creatinine level > or = 1.2 mg/dL, blood urea nitrogen level > or = 25 mg/dL, or serum sodium level < or = 130 mEq/L) were included in a randomized controlled trial aimed at comparing norfloxacin (35 patients) vs placebo (33 patients) in the primary prophylaxis of spontaneous bacterial peritonitis. The main end points of the trial were 3-month and 1-year probability of survival. Secondary end points were 1-year probability of development of spontaneous bacterial peritonitis and hepatorenal syndrome.Results Norfloxacin administration reduced the 1-year probability of developing spontaneous bacterial peritonitis (7% vs 61%, P < .001) and hepatorenal syndrome (28% vs 41%, P = .02), and improved the 3-month (94% vs 62%, P = .003) and the 1-year (60% vs 48%, P = .05) probability of survival compared with placebo.Conclusions Primary prophylaxis with norfloxacin has a great impact in the clinical course of patients with advanced cirrhosis. It reduces the incidence of spontaneous bacterial peritonitis, delays the development of hepatorenal syndrome, and improves survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to norfloxacin, rifaximin has been noted to increased survival in patients with advanced liver cirrhosis in several small-scale trials92–95.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [92]
In the citing paper
“Clinical trials in patients with advanced cirrhosis have shown that long-term use of orally administered norfloxacin is safe, produces a marked reduction of gram-negative bacteria in the faecal microbiota109, reduces the 1-year probability of developing spontaneous bacterial peritonitis and hepatorenal syndrome and improves 3-month survival92.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [92]
In the citing paper
“Clinical trials in patients with advanced cirrhosis have shown that long-term use of orally administered norfloxacin is safe, produces a marked reduction of gram-negative bacteria in the faecal microbiota109, reduces the 1-year probability of developing spontaneous bacterial peritonitis and hepatorenal syndrome and improves 3-month survival92.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [92]
In the citing paper
“Moreover, several small-scale clinical studies have suggested that antibiotics such as norfloxacin and rifaximin increase survival in patients with liver cirrhosis92–95.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [92]
In the citing paper
“Clinical trials in patients with advanced cirrhosis have shown that long-term use of orally administered norfloxacin is safe, produces a marked reduction of gram-negative bacteria in the faecal microbiota109, reduces the 1-year probability of developing spontaneous bacterial peritonitis and hepatorenal syndrome and improves 3-month survival92.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis
Arroyo, V., Ginès, P., Gerbes, A. L., Dudley, F. J., Geñtilini, P., Laffi, G., Reynolds, T. B., Ring‐Larsen, H., & Schölmerich, J. (1996) · Hepatology · doi:10.1002/hep.510230122 · Cited by 1,694
Self-citationSort, P., Navasa, M., Arroyo, V., Aldeguer, X., Planas, R., Ruíz-del-Árbol, L., Castells, L., Vargas, V., Soriano, G., Guevara, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410603 · Cited by 1,636
Self-citationDiagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document
Rimola, A., García–Tsao, G., Navasa, M., Piddock, L. J. V., Planas, R., Bernard‐Chabert, B., & Inadomi, J. M. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80201-9 · Cited by 1,058
Self-citationFernández, J., Navasa, M., Gómez, J., Colmenero, J., Vila, J., Arroyo, V., & Rodés, J. (2002) · Hepatology · doi:10.1053/jhep.2002.30082 · Cited by 954
Self-citationIncidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites
Ginés, À., Escorsell, À., Ginès, P., Saló, J., Jiménez, W., Inglada, L., Navasa, M., Clària, J., Rimola, A., Arroyo, V., et al. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90031-7 · Cited by 874
Self-citationGinés, P., Rimola, A., Planas, R., Vargas, V., Marco, F., Almela, M., Forne, M., Miranda, M. L., Llach, J., Salmerón, J. M., et al. (1990) · Hepatology · doi:10.1002/hep.1840120416 · Cited by 627
Self-citationFollo, A., Llovet, J. M., Navasa, M., Planas, R., Forns, X., Francitorra, A., Rimola, A., Gassull, M. A., Arroyo, V., & Rodés, J. (1994) · Hepatology · doi:10.1002/hep.1840200619 · Cited by 597
Self-citationCirculatory function and hepatorenal syndrome in cirrhosis†
Ruíz-del-Árbol, L., Monescillo, A., Arocena, C., Valer, P., Ginès, P., Moreira, V., Milicua, J. M., Jiménez, W., & Arroyo, V. (2005) · Hepatology · doi:10.1002/hep.20766 · Cited by 584
Self-citationRuíz-del-Árbol, L., Urmán, J., Fernández, J., González, M., Navasa, M., Monescillo, A., Albillos, A., Jiménez, W., & Arroyo, V. (2003) · Hepatology · doi:10.1053/jhep.2003.50447 · Cited by 496
Self-citationLlach, J., Ginès, P., Arroyo, V., Rimola, A., Titó, L., Badalamenti, S., Jiménez, W., Gaya, J., Rivera, F., & Rodés, J. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90441-6 · Cited by 457
Self-citation
Cited by
Sorted by citations
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka, J., Krag, A. A., Laleman, W., & Ginès, P. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.024 · Cited by 3,033
Self-citationTsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60121-5 · Cited by 1,892
(2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.004 · Cited by 1,738
Arvaniti, V., D’Amico, G., Fede, G., Manousou, P., Tsochatzis, E. A., Pleguezuelo, M., & Burroughs, A. K. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.019 · Cited by 1,179
Management of adult patients with ascites due to cirrhosis
Runyon, B. A. (2009) · Hepatology · doi:10.1002/hep.22853 · Cited by 986
Metadata
- Authors
- Fernández, J., Navasa, M., Planas, R., Montoliu, S., Monfort, D., Soriano, G., Vila, C., Pardo, A., Quintero, E., Vargas, V., Such, J., Ginès, P., & Arroyo, V.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
- Hospital de Sant Pau (ES)
- Hospital Del Mar (ES)
- Hospital Universitario de Canarias (ES)
- Corresponding author
- Navasa, Miquel
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 133
- Issue
- 3
- Pages
- 818-824
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2012746560
- Cited by
- 709
- References
- 36
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 23 · 2023: 37 · 2022: 28 · 2021: 43 · 2020: 39 · 2019: 42 · 2018: 42 · 2017: 37 · 2016: 34 · 2015: 55 · 2014: 48 · 2013: 31 · 2012: 46
- FWCI
- 30.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Abdominal vascular conditions and treatments
- Keywords
- spontaneous bacterial peritonitis, primary prophylaxis, norfloxacin, hepatorenal syndrome, liver cirrhosis, survival, renal dysfunction, antibiotic prophylaxis
- MeSH terms
- Aged, Anti-Infective Agents, Double-Blind Method, Female, Hepatorenal Syndrome, Humans, Liver Cirrhosis, Male, Middle Aged, Norfloxacin, Peritonitis, Risk Factors, Survival Analysis, Antibiotic Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
